CD8A and neoplasm: Recent studies have revealed that Siglecs family genes can regulate the interaction between immune cells and tumor cells by sialic acid‐dependent mechanisms, indicating that these Siglecs could be potential targets in checkpoint therapy.[43, 44, 45] In this study we demonstrate that the expression of Siglec‐G was significantly increased on both human and murine CD8+ and CD4+ TILs.